S
MIRM icon

SignatureFD’s Mirum Pharmaceuticals MIRM Stock Holding History

SignatureFD’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.7K Sell
170
-8
-4% -$753 ﹤0.01% 2314
2025
Q4 		$14.1K Sell
178
-12
-6% -$861 ﹤0.01% 2269
2025
Q3 		$13.9K Buy
190
+10
+6% +$636 ﹤0.01% 2273
2025
Q2 		$9.16K Sell
180
-35
-16% -$1.56K ﹤0.01% 2381
2025
Q1 		$9.69K Hold
215
– – ﹤0.01% 2371
2024
Q4 		$8.89K Sell
215
-6
-3% -$250 ﹤0.01% 2408
2024
Q3 		$8.62K Buy
221
+41
+23% +$1.64K ﹤0.01% 2386
2024
Q2 		$6.15K Buy
180
+10
+6% +$262 ﹤0.01% 2445
2024
Q1 		$4.27K Sell
170
-4
-2% -$110 ﹤0.01% 2586
2023
Q4 		$5.14K Buy
174
+4
+2% +$121 ﹤0.01% 2486
2023
Q3 		$5.37K Hold
170
– – ﹤0.01% 2463
2023
Q2 		$4.4K Sell
170
-5
-3% -$133 ﹤0.01% 2553
2023
Q1 		$4.2K Buy
175
+152
+661% +$3.46K ﹤0.01% 2577
2022
Q4 		$449 Buy
+23
New +$455 ﹤0.01% 3119

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SignatureFD's MIRM Position: Q1 2026 in Review

SignatureFD reduced its Mirum Pharmaceuticals (MIRM) stake by 4.5% in Q1 2026, selling an estimated $753 and leaving 170 shares worth $15.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2314.

SignatureFD first reported a position in MIRM in Q4 2022 and has held it in 14 quarters since. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • SignatureFD held 170 shares of Mirum Pharmaceuticals worth $15.7K as of Q1 2026.
  • SignatureFD sold 8 Mirum Pharmaceuticals shares in Q1 2026, an estimated $753.
  • Mirum Pharmaceuticals made up ﹤0.01% of SignatureFD's portfolio in Q1 2026, its #2314 holding.
  • SignatureFD first reported a position in Mirum Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.